Shopping Cart
Remove All
Your shopping cart is currently empty
Crefmirlimab
(Synonyms: 89Zr-Df-IAB22M2C) Copy Product Info
🥰Excellent
Synonyms: 89Zr-Df-IAB22M2C
Catalog No. T82670 Copy Product Info
🥰Excellent
Crefmirlimab (IAB22M2C) is a humanized anti-CD8 monoclonal antibody fragment (minibody) designed for PET imaging. Upon radiolabeling (e.g., with 89Zr), it serves as a non-invasive imaging biomarker that binds with high affinity and specificity to the CD8 receptor on CD8+ T cells, enabling real-time, dynamic tracking of T-cell distribution, infiltration, and trafficking in vivo in both preclinical models and clinical studies. It is a critical tool for evaluating the pharmacodynamics of T-cell engaging therapies (such as the GUCY2C-CD3 bispecific antibody PF-07062119) and for investigating the tumor immune microenvironment
Cas No. 2611099-93-3
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $297 | 4-6 weeks | 4-6 weeks | |
| 5 mg | $912 | 4-6 weeks | 4-6 weeks | |
| 10 mg | $1,430 | 4-6 weeks | 4-6 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Crefmirlimab (IAB22M2C) is a humanized anti-CD8 monoclonal antibody fragment (minibody) designed for PET imaging. Upon radiolabeling (e.g., with 89Zr), it serves as a non-invasive imaging biomarker that binds with high affinity and specificity to the CD8 receptor on CD8+ T cells, enabling real-time, dynamic tracking of T-cell distribution, infiltration, and trafficking in vivo in both preclinical models and clinical studies. It is a critical tool for evaluating the pharmacodynamics of T-cell engaging therapies (such as the GUCY2C-CD3 bispecific antibody PF-07062119) and for investigating the tumor immune microenvironment |
| In vitro | In cell-binding assays, Crefmirlimab (IAB22M2C) demonstrates high specificity and binding affinity for CD8 receptors expressed on human T cells, enabling sensitive detection and quantification of CD8+ populations without inducing significant T-cell activation or effector functions [1]. |
| In vivo | In tumor-bearing mice, IV injection of radiolabeled Crefmirlimab (89Zr-Df-IAB22M2C) enables PET imaging to track the dynamic infiltration of CD8+ T cells into tumors and lymphoid organs. The study confirms its utility as a non-invasive biomarker for assessing therapeutic response and immune activation [1]. |
| Synonyms | 89Zr-Df-IAB22M2C |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | CD8 |
| Cas No. | 2611099-93-3 |
| Isotype | IgG1 |
| Storage | Store at low temperature Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Preview
Related Tags: Crefmirlimab chemical structure | Crefmirlimab in vivo | Crefmirlimab in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.